Edgewise Therapeutics (EWTX)
(Real Time Quote from BATS)
$22.25 USD
-0.62 (-2.71%)
Updated Jul 16, 2024 03:45 PM ET
2-Buy of 5 2
D Value F Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EWTX 22.25 -0.62(-2.71%)
Will EWTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EWTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EWTX
Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know
Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?
EWTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 70.76%: Read This Before Placing a Bet
Edgewise (EWTX) Rallies 35% on Issue of New Common Stock
Wall Street Analysts See a 310.1% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?
Other News for EWTX
Wedbush reveals three potential buyout targets for Biogen
Edgewise Therapeutics added to Best Ideas List at Wedbush
Edgewise Therapeutics management to meet with Piper Sandler
Edgewise Therapeutics management to meet with Piper Sandler
Truist Financial Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX)